Kringle Pharma, Inc.
4884・Growth Market・Pharmaceuticals
Governance
Company with a Board of Corporate Auditors. The Board of Directors consists of 7 directors (2 of whom are outside directors, an outside director ratio of approximately 28.6%), and a Board of Corporate Auditors composed entirely of 3 outside corporate auditors has been established. The Board of Directors met 18 times during the fiscal year under review, with full attendance. A Nomination Committee and a Compensation Committee have not been established. A Compliance and Risk Management Committee has been established under the Board of Directors.
Risk Management
The Company has established the "Risk Management Regulations" and "Compliance Regulations," building a system in which the Compliance and Risk Management Committee (meeting once per quarter), reporting directly to the Board of Directors, centrally identifies, evaluates, and prevents various risks. In the event of a serious incident, a task force headed by the President and Representative Director is established to minimize damage and prevent recurrence.
Shareholder Returns
No dividends have been paid since the company's founding. The dividend forecast per share is ¥0 for both the interim and full year of FY2026 (ending September 2026). Retained earnings are negative (¥-2,189 million), leaving no distributable profit, so the company plans to continue paying no dividends for the time being.
Dividend Policy
The company has not paid dividends from retained earnings since its founding. The annual dividend for FY2025 (ended September 2025) was ¥0, and the dividend forecast for FY2026 (ending September 2026) is also ¥0 (both interim and year-end). As retained earnings at the end of the current interim accounting period stood at ¥-2,189 million, there is no distributable profit, and the company plans to remain dividend-free for the time being. The policy is to consider dividend payments once the company has achieved sufficient and recurring profits in the future.
ESG
Positions the corporate philosophy of "contributing to society through research and development of treatments for intractable diseases" at the core of its sustainability approach. As part of its human capital strategy, the company has implemented full flextime, remote work, DE&I promotion, and stock option programs. The proportion of women in managerial positions stands at 25.0%, and the gender pay gap (all workers) is 91.5%. Quantitative ESG indicators and targets have not yet been established, and the company is currently considering whether such targets are necessary going forward.
Last updated: December 19, 2025